Early oral stepdown antibiotic therapy versus continuing intravenous therapy for uncomplicated Gram-negative bacteraemia (the INVEST trial): study protocol for a multicentre, randomised controlled, open-label, phase III, non-inferiority trial

BACKGROUND: The incidence of Gram-negative bacteraemia is rising globally and remains a major cause of morbidity and mortality. The majority of patients with Gram-negative bacteraemia initially receive intravenous (IV) antibiotic therapy. However, it remains unclear whether patients can step down to...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, I. Russel, Tong, Steven Y. C., Davis, Joshua S., Paterson, David L., Syed-Omar, Sharifah F., Peck, Kwong Ran, Chung, Doo Ryeon, Cooke, Graham S., Libau, Eshele Anak, Rahman, Siti-Nabilah B. A., Gandhi, Mihir P., Shi, Luming, Zheng, Shuwei, Chaung, Jenna, Tan, Seow Yen, Kalimuddin, Shirin, Archuleta, Sophia, Lye, David C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9295110/
https://www.ncbi.nlm.nih.gov/pubmed/35854360
http://dx.doi.org/10.1186/s13063-022-06495-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9295110/
https://www.ncbi.nlm.nih.gov/pubmed/35854360
http://dx.doi.org/10.1186/s13063-022-06495-3

Ejemplares similares